Metabolic analysis of brain tumors using advanced MRI techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to utilize high-field magnetic resonance imaging (MRI) technologies, specifically 3 Tesla and 7 Tesla scanners, to enhance metabolic spectroscopic imaging (MRSI) and chemical exchange saturation transfer imaging (CEST) for the characterization of brain tumors, particularly gliomas. The focus is on measuring the presence of 2-hydroxy-glutarate (2HG), a metabolite indicative of IDH mutations in gliomas, which are associated with improved patient survival. A total of 75 patients with suspected brain masses and 50 healthy controls will be examined to evaluate the effectiveness of these imaging techniques in preoperative IDH-status prediction. The study seeks to improve diagnostic accuracy and treatment planning for patients with brain tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy people who are able to lie in the MR scanner for one hour;
* Patients with suspected mass in the brain
* Written informed consent

Exclusion Criteria:

* Persons under the age of 18
* Persons who are mentally unable to choose to participate
* Pregnant women
* Patients with oncological findings or neurodegenerative findings in the past
* Wearing active implants (e.g. pacemakers and neurostimulators)
* Emergency patients
* Persons with tattoos on the head or neck area

Where it's running

• Institute for Diagnostic and Interventional Neuroradiology, University Hospital Bern
  Bern, Switzerland Recruiting

Study contacts

• Study coordinator: Johannes Slotboom, PhD
• Email: johannes.slotboom@gmail.com
• Phone: +41316327469

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient experiences during treatment for IDH‑mutant grade 2 gliomas: vorasidenib, radiotherapy, or observation

  This project will test how adults with IDH‑mutant grade 2 gliomas feel—their quality of life, treatment symptoms, and anxiety—when they receive vorasidenib, radiotherapy, or active surveillance.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT07547163

• Combining TIL Therapy and Pembrolizumab for Advanced Brain Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with Pembrolizumab to see if it helps people with advanced brain cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06640582

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Using MRI to Differentiate Between Brain Tumors and Radiation Effects

  This study is testing a new MRI technique to see if it can help tell the difference between brain tumors and radiation damage in people who have had radiation therapy.

  Recruiting at 2 sites Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT06101069

• Detecting microplastics in patients undergoing neurosurgery

  This study is trying to see if tiny pieces of plastic are found in the blood, brain fluid, and brain tissue of patients who are having brain surgery.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT05968053

• HOPE: Clinical, Pathology, and Imaging Project for Brain Tumors

  This project collects clinical records, MRI scans, and pathology data from people with glioma and other primary brain tumors to build large databases for improving diagnosis and care.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT05859659

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.